ATG16L1

Across TCGA pan-cancer cohorts, ATG16L1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATG16L1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ATG16L1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATG16L1 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and LSCC are the cancer types where ATG16L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG16L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.157	<.001	6	view →
CCRCC	All	All	+0.103	<.001	6	view →
LSCC	All	All	−0.099	<.001	5	view →
COAD	All	All	−0.075	.005	5	view →
PDAC	Male	All	+0.146	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATG16L1–HNSC

Open the HNSC breakdown →